Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 30;10(1):39.
doi: 10.1038/s41572-024-00523-z.

Trigeminal neuralgia

Affiliations
Review

Trigeminal neuralgia

Sait Ashina et al. Nat Rev Dis Primers. .

Abstract

Trigeminal neuralgia (TN) is a facial pain disorder characterized by intense and paroxysmal pain that profoundly affects quality of life and presents complex challenges in diagnosis and treatment. TN can be categorized as classical, secondary and idiopathic. Epidemiological studies show variable incidence rates and an increased prevalence in women and in the elderly, with familial cases suggesting genetic factors. The pathophysiology of TN is multifactorial and involves genetic predisposition, anatomical changes, and neurophysiological factors, leading to hyperexcitable neuronal states, central sensitization and widespread neural plasticity changes. Neurovascular compression of the trigeminal root, which undergoes major morphological changes, and focal demyelination of primary trigeminal afferents are key aetiological factors in TN. Structural and functional brain imaging studies in patients with TN demonstrated abnormalities in brain regions responsible for pain modulation and emotional processing of pain. Treatment of TN involves a multifaceted approach that considers patient-specific factors, including the type of TN, with initial pharmacotherapy followed by surgical options if necessary. First-line pharmacological treatments include carbamazepine and oxcarbazepine. Surgical interventions, including microvascular decompression and percutaneous neuroablative procedures, can be considered at an early stage if pharmacotherapy is not sufficient for pain control or has intolerable adverse effects or contraindications.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Cruccu, G., Di Stefano, G. & Truini, A. Trigeminal neuralgia. N. Engl. J. Med. 383, 754–762 (2020). - PubMed - DOI
    1. Headache classification committee of the International Headache Society (IHS) the International Classification of Headache Disorders, 3rd edition. Cephalalgia 38, 1–211 (2018).
    1. Cruccu, G. et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology 87, 220–228 (2016). - PubMed - PMC - DOI
    1. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 40, 129–221 (2020).
    1. Bendtsen, L. et al. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. Lancet Neurol. 19, 784–796 (2020). - PubMed - DOI

MeSH terms

LinkOut - more resources